Cannabis company Emerald Health Therapeutics Inc (CVE:EMH, OTCQX:EMHTF) is looking to strengthen its intellectual property portfolio via a partnership with cannabis-focused research facility VivaCell Biotechnologies.
The institute will work with Emerald Health, evaluating formulas and determining consistent dosages as the company continues to develop medical and recreational cannabis products.
Emerald Health is a licensed producer authorized by Health Canada to grow, sell and produce cannabis across the country.
“There are a rare few organizations that focus their understanding of the cannabis plant at the heart of its scientific development and strategic operations,” said Emerald CEO Chris Wagner.
The institute partners with academic research centers in Spain like the University of Córdoba, Complutense University of Madrid, Instituto Cajal in Madrid as well as Italy's University of Piemonte Orientale.
The company currently holds 17 patents filed and hopes the data stemming from this partnership will translate into more in the future.
“Our goal is to expand our product pipeline with innovative products substantiated by scientific data and protected by our intellectual property,” added Wagner.
VivaCell is a wholly-owned subsidiary of Emerald Health Sciences, which has a 32% stake in Emerald Health Therapeutics Inc.
Shares of Emerald Health were up slightly to $3.89 by the closing bell Tuesday.